RU2496786C2 - Пептидные аналоги альфа-меланоцитстимулирующего гормона - Google Patents

Пептидные аналоги альфа-меланоцитстимулирующего гормона Download PDF

Info

Publication number
RU2496786C2
RU2496786C2 RU2010153217/04A RU2010153217A RU2496786C2 RU 2496786 C2 RU2496786 C2 RU 2496786C2 RU 2010153217/04 A RU2010153217/04 A RU 2010153217/04A RU 2010153217 A RU2010153217 A RU 2010153217A RU 2496786 C2 RU2496786 C2 RU 2496786C2
Authority
RU
Russia
Prior art keywords
xaa
msh
ser
ala
trp
Prior art date
Application number
RU2010153217/04A
Other languages
English (en)
Russian (ru)
Other versions
RU2010153217A (ru
Inventor
Майкл А. ПЕРРИКОНЕ
Джон Лайл ДЗУРИС
Тимоти Е. ВИДЕН
Джеймс Е. СТЕФАНО
Кларк К. ПАН
Андреа Е. ЭДЛИНГ
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of RU2010153217A publication Critical patent/RU2010153217A/ru
Application granted granted Critical
Publication of RU2496786C2 publication Critical patent/RU2496786C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/34—Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
RU2010153217/04A 2008-05-27 2009-03-20 Пептидные аналоги альфа-меланоцитстимулирующего гормона RU2496786C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5637308P 2008-05-27 2008-05-27
US61/056,373 2008-05-27
PCT/US2009/037809 WO2009151708A2 (en) 2008-05-27 2009-03-20 Peptide analogs of alpha-melanocyte stimulating hormone

Publications (2)

Publication Number Publication Date
RU2010153217A RU2010153217A (ru) 2012-07-10
RU2496786C2 true RU2496786C2 (ru) 2013-10-27

Family

ID=41278142

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010153217/04A RU2496786C2 (ru) 2008-05-27 2009-03-20 Пептидные аналоги альфа-меланоцитстимулирующего гормона

Country Status (16)

Country Link
US (4) US8440793B2 (OSRAM)
EP (2) EP2816055B1 (OSRAM)
JP (4) JP5624027B2 (OSRAM)
KR (4) KR101810110B1 (OSRAM)
CN (2) CN102143970B (OSRAM)
AU (1) AU2009258054B2 (OSRAM)
BR (1) BRPI0912141A2 (OSRAM)
CA (2) CA2998948A1 (OSRAM)
DK (2) DK2816055T3 (OSRAM)
ES (2) ES2715329T3 (OSRAM)
IL (3) IL209369A (OSRAM)
MX (3) MX356295B (OSRAM)
PT (2) PT2297178E (OSRAM)
RU (1) RU2496786C2 (OSRAM)
TR (1) TR201903610T4 (OSRAM)
WO (1) WO2009151708A2 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766340C1 (ru) * 2021-02-10 2022-03-15 Игорь Закванович Зайцев Пептидный толерогенный компаунд

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101810110B1 (ko) * 2008-05-27 2017-12-18 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체
CN101914138A (zh) * 2010-07-13 2010-12-15 华东师范大学 一种用偶联剂制得的肝癌靶向肽-阿霉素及合成方法
CN102008732B (zh) * 2010-11-08 2012-10-24 武汉华耀生物医药有限公司 一种叶酸偶联抗体药物及其制备方法与应用
WO2012158960A2 (en) 2011-05-17 2012-11-22 H. Lee Moffitt Cancer Center & Research Institute, Inc. Melanocortin 1 receptor ligands and methods of use
MX365620B (es) 2012-11-21 2019-06-07 Univ Cincinnati Composiciones para el cuidado de la piel y metodos que comprenden agonistas selectivos del receptor de melanocortina 1.
WO2015067503A1 (en) * 2013-11-07 2015-05-14 Clinuvel Ag Alpha-msh analogues for use in the treatment of psoriasis
US20170360896A1 (en) * 2014-10-28 2017-12-21 Clinuvel Ag Inflammatory disease
WO2017019664A1 (en) 2015-07-28 2017-02-02 University Of Iowa Research Foundation Compositions and methods of treating cancer
SG10201506686WA (en) * 2015-08-24 2017-03-30 Agency Science Tech & Res Conjugates
CN106905432B (zh) * 2015-12-18 2018-12-21 兰州大学 一种α促黑素细胞激素的融合蛋白及其制备方法和应用
EP3448872A4 (en) * 2016-04-27 2019-12-11 The Regents of the University of California PREPARATION OF FUNCTIONAL HOMOCYSTEINRESTES IN POLYPEPTIDES AND PEPTIDES
US20220072092A1 (en) * 2016-06-24 2022-03-10 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US11179484B2 (en) 2016-06-24 2021-11-23 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US11591367B2 (en) 2016-10-04 2023-02-28 Dsm Ip Assets B.V. Melanocortin-1-receptor agonists
KR101957014B1 (ko) * 2017-04-18 2019-06-20 순천대학교 산학협력단 항염증 활성을 나타내는 펩타이드 및 이를 유효성분으로 포함하는 항염증용 조성물
KR20220070246A (ko) 2019-09-23 2022-05-30 디디에스 리서치 인크. 침투 증진제를 갖는 지질 소포 조성물
US20230058316A1 (en) * 2020-02-07 2023-02-23 Ewha University - Industry Collaboration Foundation Pegylated ige-dependent histamine-releasing factor (hrf)-binding peptide and use thereof
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
MX2023011157A (es) 2021-03-24 2024-01-25 Glo Pharma Inc Peptidos y metodos para reducir la pigmentacion de la piel.
WO2023091689A1 (en) 2021-11-19 2023-05-25 University Of Iowa Research Foundation Combined use of mcr1-directed radiotherapy and immune checkpoint inhibition in the treatment of melanoma
WO2025156020A2 (en) * 2025-03-12 2025-07-31 Ademoviċ Zlatko Peptide combination for the control of aldosterone synthesis in the function of pressure control and disorders due to infectious and other diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120588A2 (en) * 2004-05-26 2005-12-22 The Curators Of The University Of Missouri Peptides delivered to cell nuclei
RU2380372C2 (ru) * 2005-07-08 2010-01-27 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик С.А.С. Лиганды рецепторов меланокортинов

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US4542225A (en) * 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4952394A (en) 1987-11-23 1990-08-28 Bristol-Myers Company Drug-monoclonal antibody conjugates
US5194425A (en) * 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
US5137877B1 (en) * 1990-05-14 1996-01-30 Bristol Myers Squibb Co Bifunctional linking compounds conjugates and methods for their production
US5618528A (en) * 1994-02-28 1997-04-08 Sterling Winthrop Inc. Biologically compatible linear block copolymers of polyalkylene oxide and peptide units
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
US5858401A (en) 1996-01-22 1999-01-12 Sidmak Laboratories, Inc. Pharmaceutical composition for cyclosporines
EP0975374B1 (en) * 1996-07-12 2007-12-05 Immunomedics, Inc. Radiometal-binding peptide analogues
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
US20020193332A1 (en) * 2001-02-12 2002-12-19 Hedley Mary Lynne Methods of treating bladder disorders
US6969702B2 (en) * 2002-11-20 2005-11-29 Neuronova Ab Compounds and methods for increasing neurogenesis
EP2004841A4 (en) * 2006-04-05 2009-09-02 Univ California COMPOSITIONS AND METHODS FOR THE ANALYSIS AND TREATMENT OF AIDS WASTING SYNDROME AND IMMUNOCELL DYNAMIC FUNCTION
FR2914646A1 (fr) 2007-04-04 2008-10-10 Neorphys Soc Par Actions Simpl Analogues peptidiques des recepteurs des melanocortines
US8069129B2 (en) * 2007-04-10 2011-11-29 Ab Initio Technology Llc Editing and compiling business rules
CN101302245B (zh) 2007-05-09 2011-11-16 中国人民解放军军事医学科学院毒物药物研究所 黑色素皮质激素受体四肽类激动剂及其制备方法和用途
KR101810110B1 (ko) * 2008-05-27 2017-12-18 젠자임 코포레이션 알파-멜라노사이트 자극 호르몬의 펩티드 유사체

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005120588A2 (en) * 2004-05-26 2005-12-22 The Curators Of The University Of Missouri Peptides delivered to cell nuclei
RU2380372C2 (ru) * 2005-07-08 2010-01-27 Сосьете Де Консей Де Решерш Э Д'Аппликасьон Сьентифик С.А.С. Лиганды рецепторов меланокортинов

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MASMAN M F ET AL. "Synthesis and conformational analysis of His-Phe-Arg-Trp-NH2 and analogues with antifungal properties. BIOORGANIC & MEDICINAL CHEMIST No.22 p. 7604-7614. *
VAGNER JOSEF ЕТ AL. Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: Homooligomers of alpha-MSH." BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, v. 14, No.1, p. 211-215. *
VAGNER JOSEF ЕТ AL. Novel targeting strategy based on multimeric ligands for drug delivery and molecular imaging: Homooligomers of alpha-MSH." BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2004, v. 14, №1, p. 211-215. MASMAN M F ET AL. "Synthesis and conformational analysis of His-Phe-Arg-Trp-NH2 and analogues with antifungal properties. BIOORGANIC & MEDICINAL CHEMISTRY, 2006, v.14, №22 p. 7604-7614. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2766340C1 (ru) * 2021-02-10 2022-03-15 Игорь Закванович Зайцев Пептидный толерогенный компаунд
WO2022173328A1 (ru) * 2021-02-10 2022-08-18 Игорь Закванович Зайцев Пептидный толерогенный компаунд

Also Published As

Publication number Publication date
PT2816055T (pt) 2019-03-18
JP2014210805A (ja) 2014-11-13
CN102143970B (zh) 2017-02-08
ES2715329T3 (es) 2019-06-03
US20170313756A1 (en) 2017-11-02
KR20160092046A (ko) 2016-08-03
KR101810110B1 (ko) 2017-12-18
EP2816055B1 (en) 2018-12-19
US9115174B2 (en) 2015-08-25
EP2816055A1 (en) 2014-12-24
IL209369A0 (en) 2011-01-31
WO2009151708A3 (en) 2010-11-18
CN107098957A (zh) 2017-08-29
RU2010153217A (ru) 2012-07-10
DK2816055T3 (en) 2019-04-01
CN102143970A (zh) 2011-08-03
MX2018006299A (es) 2021-11-11
CA2726076C (en) 2018-04-10
CA2726076A1 (en) 2009-12-17
US20130303452A1 (en) 2013-11-14
AU2009258054A1 (en) 2009-12-17
US9738698B2 (en) 2017-08-22
TR201903610T4 (tr) 2019-03-21
IL209369A (en) 2017-05-29
AU2009258054B2 (en) 2014-03-20
WO2009151708A2 (en) 2009-12-17
IL252058A0 (en) 2017-07-31
DK2297178T3 (da) 2014-09-01
JP2011521949A (ja) 2011-07-28
EP2297178B1 (en) 2014-07-30
KR101666631B1 (ko) 2016-10-17
EP2297178A2 (en) 2011-03-23
US20090297444A1 (en) 2009-12-03
JP6585099B2 (ja) 2019-10-02
US10385108B2 (en) 2019-08-20
ES2492670T3 (es) 2014-09-10
MX356295B (es) 2018-05-22
KR20180118250A (ko) 2018-10-30
JP2019065053A (ja) 2019-04-25
US8440793B2 (en) 2013-05-14
CA2998948A1 (en) 2009-12-17
JP6170019B2 (ja) 2017-07-26
PT2297178E (pt) 2014-08-26
JP5624027B2 (ja) 2014-11-12
BRPI0912141A2 (pt) 2016-07-26
IL245906A0 (en) 2016-07-31
MX2010012990A (es) 2011-05-25
US20160046688A1 (en) 2016-02-18
JP2017061573A (ja) 2017-03-30
KR20110050593A (ko) 2011-05-16
KR20170102050A (ko) 2017-09-06

Similar Documents

Publication Publication Date Title
JP6585099B2 (ja) α−メラニン形成細胞刺激ホルモンのペプチド類似体
US20050171014A1 (en) Conjugates of ligand linker and cytotoxic agent and related composition and methods of use
ES2950789T3 (es) Polipéptidos de apelina
CN101268099A (zh) 用于治疗性干预的y4选择性受体激动剂
AU2022222674A1 (en) Glucagon-like peptide-1 receptor antagonists
US11141452B2 (en) Bifunctional compounds for relief of pain comprising an opioid receptor agonist moiety and a NK1 receptor antagonist moiety and methods for treating pain
AU2023320411A1 (en) Glucagon-like peptide-1 receptor antagonists
HK1160656A (zh) α-促黑素細胞激素的肽類似物
HK1160656B (en) Peptide analogs of alpha-melanocyte stimulating hormone
HK1242610A1 (en) Methods for reducing cd36 expression
HK1197994B (en) Methods for reducing cd36 expression

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20190321